Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior radiotherapy (RT): At least four weeks since completion of whole-brain irradiation, at least two weeks since completion of prophylactic cranial irradiation, and to any other site.
Patients must have had their last fraction of: \r\n* Craniospinal irradiation (>  GRAY [Gy]) or total body irradiation >  weeks prior to enrollment\r\n* Focal irradiation >  weeks prior to enrollment\r\n* >=  months since autologous bone marrow/stem cell transplant prior to enrollment
Patient has received radiation therapy prior to study registration; patients must have had their last fraction of local irradiation to the primary tumor >=  months prior to registration, their last fraction of craniospinal irradiation (>=  Gy) or total body irradiation >=  months prior to registration or >=  weeks (wks) for the therapeutic doses of MIBG; patient has not received focal irradiation for symptomatic metastatic sites within  days prior to registration
Prior total body or hemi-body irradiation
Subject who has received prior pelvic irradiation or is scheduled for pelvic nodal irradiation
Radiation therapy within  weeks prior to randomization, including stereotactic or partial brain irradiation. Whole brain irradiation within  weeks prior to randomization
Radiation: patients must have:\r\n* Had their last fraction of local irradiation to primary tumor >=  weeks prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression\r\n* Had their last fraction of craniospinal irradiation or total body irradiation >=  weeks prior to registration
Participants may have received prior cranial irradiation
Disease has progressed through at least one systemic therapy or through local irradiation within the preceding  months.
Radiotherapy: patients must have had their last fraction of: \r\n* Focal irradiation >  weeks prior to enrollment
Prior prophylactic cranial irradiation (PCI) is allowed
Radiation: patients must have:\r\n* Had their last fraction of local irradiation to primary tumor >=  months prior to registration; investigators are reminded to review potentially eligible cases to avoid confusion with pseudo-progression\r\n* Had their last fraction of craniospinal irradiation (>  Gy) >  months prior to registration
Prior irradiation to > % of BM reserves (including total body irradiation), regardless of the washout period;
Prior radiation: Cranial irradiation, total body irradiation (TBI), or ? % radiation of pelvis ?  months prior to screening. Focal irradiation: ?  weeks prior to screening if radiation field involved a nontarget lesion; ?  weeks prior to screening if radiation field involved a target lesion. Note: True disease progression following prior irradiation therapy must be confirmed by Investigator prior to screening.  Bone marrow transplant: <  months since allogeneic bone marrow transplant prior to screening. <  months since autologous bone marrow/stem cell transplant prior to screening. <  months since stem cell transplant (SCT) or Rescue without TBI with no evidence of GVHD prior to screening.  Radioisotopes: fluorothymidine (FLT) ?  hours prior to first dose of study drug
Plans to administer irradiation to the breast only
Prior whole brain irradiation
Previous pelvic irradiation therapy
history of mediastinal or pulmonary irradiation
Prior conventional irradiation of the spine site and level to be treated with an interval shorter than  months
History of prior irradiation to the area to be treated
Treatment plan that includes regional nodal irradiation
Previous irradiation that precludes the safe administration of an additional dose of  cGy of total body irradiation (TBI)
Previous total body irradiation, or irradiation of >% of the patient's bone marrow.
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior whole brain irradiation
Prior mediastinal irradiation (for any reason)
Prior whole brain irradiation
Prior whole brain irradiation
Previous pelvic irradiation, prostate brachytherapy
Prior total body irradiation (TBI)
Prior total body irradiation, prior total abdominal or whole liver radiation
Patients must not have received previous irradiation to the brain
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Progressive intracranial ependymoma after prior focal irradiation
Prior craniospinal irradiation
Prior intracavitary irradiation or Gliadel wafers
Previous pelvic irradiation, prostate brachytherapy, or bilateral orchiectomy
Prior whole brain irradiation
Patients must have had their last fraction of: \r\n* Craniospinal irradiation (>  Gy) >  months prior to enrollment\r\n* Focal irradiation >  days prior to enrollment\r\n* Local palliative irradiation (small port) >  days
Treatment plan that includes regional nodal irradiation
Prior whole brain irradiation
Prior cranial irradiation
Patients who have received cranial or spinal irradiation less than  weeks prior to the start of this protocol
Stem cell infusions (with or without total body irradiation [TBI]): ? days
? weeks for total skin electron beam irradiation,
Patients are excluded if they have received total body irradiation (TBI)
Prior whole brain irradiation
Prior whole brain irradiation.
Patients must have:\r\n* Had their last fraction of local irradiation to primary tumor >=  weeks prior to registration\r\n* Had their last fraction of craniospinal irradiation or total body irradiation >=  weeks prior to registration
Prior neck radiotherapy that would preclude re-irradiation
Prior irradiation is allowed if >  days prior to registration have elapsed since\n             the date of last treatment.
Patients with a history of pelvic irradiation for any reason
Prior cranial irradiation
Patients who have received prior pelvic irradiation are not eligible
At least  weeks for craniospinal, ?% radiation of pelvis, or total body irradiation prior to first dose of study drug
Previous pelvic radiotherapy that would prevent prostate/seminal vesicle (SV) irradiation
No prior abdominopelvic radiotherapy is allowed except for total body irradiation administered >=  years prior; no prior systemic therapy for anal cancer
Total body irradiation (TBI) or craniospinal radiation therapy <months
Prior irradiation to lung fields
History of prior chemotherapy or pelvic irradiation
No history of previous pelvic irradiation
History of prior pelvic irradiation
Any prior melanoma treatment other than surgery or regional irradiation
The participant has undergone chest irradiation within  weeks prior to receiving study treatment.
Patients must have had their last fraction of:\r\n* Craniospinal irradiation, total body irradiation (TBI), or >= % radiation of pelvis >  months prior to enrollment\r\n* Focal irradiation >  weeks prior to enrollment\r\n* Local palliative radiation therapy (XRT) (small port) >=  weeks
Surgery or irradiation ?  weeks prior to randomization
Recommended to undergo pelvic irradiation with concurrent chemotherapy
Prior abdomino-pelvic irradiation
Prior irradiation of the spine site and level to be treated
Patients who have received previous vaginal, pelvic, or abdominal irradiation
Prior pelvic irradiation.
No history of previous chemotherapy or pelvic irradiation
History of prior chemotherapy or pelvic irradiation
Patients must not have received any prior pelvic irradiation
Patients must be at least  weeks out from pelvic irradiation, and must not have more than % of bone marrow irradiated.
Patients who have received cranial or spinal irradiation less than  weeks prior to the start of this protocol
Previous pelvic irradiation, prostate brachytherapy
RECURRENT/ PROGRESSIVE DIPG (STRATUM ): Patients must have had their last fraction of: \r\n* Craniospinal irradiation or radiation to >= % of pelvis >  months prior to enrollment\r\n* Focal irradiation to the primary site >  days prior to enrollment\r\n* Local palliative irradiation other than previously irradiated primary site (small port) >=  days
NON-PROGRESSED DIPG (STRATUM ): Patients must have had their last fraction of focal irradiation to the primary site >  days prior to enrollment; patients must not have received local palliative irradiation or craniospinal irradiation
Prior total body irradiation (TBI) making TMI not feasible
Patients who have pelvic irradiation with doses ?  Grays (Gy).
At least  days from prior total body irradiation (TBI)
Patient had a resection and/or completed a course of cranial irradiation; and
Patients with prior whole brain irradiation
Prior history of pelvic irradiation
History of extensive prior pelvic irradiation.
Has undergone chest irradiation within  weeks prior to randomization (except palliative irradiation of bone lesions)
External radiation therapy (XRT): Must not have received XRT within  months prior to study entry for craniospinal irradiation (>  Gy) or total body irradiation or if >= % radiation of pelvis; >=  weeks for local irradiation to primary tumor; >=  weeks for focal irradiation for symptomatic metastatic sites
Prior whole brain irradiation
Evidence or suspected recurrent or metastatic disease; prior brain irradiation is not allowed
Participants with a history of pelvic irradiation; or chemotherapy or radiotherapy within the preceding  days
Disease-based radiation therapy (not total body irradiation)
Patients receiving prior external beam irradiation to the head or neck, including any form of stereotactic irradiation
Regional nodal irradiation is part of the treatment plan
Subjects who have previously received or have planned Total Body Irradiation (TBI)
Patient has received or is scheduled to receive total body irradiation, total nodal irradiation, upper abdomen radiotherapy, half or upper body irradiation, radiotherapy of the cranium, craniospinal regions, head and neck, lower thorax region or the pelvis within  week prior to study entry (Day ) or within  h after start of chemotherapy administration on Day .
Indications for comprehensive regional nodal irradiation
Prior pelvic irradiation
History of re-irradiation to a field which includes the carotid arteries